Navigation Links
Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood

X15-070 is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma and in myelofibrosis with myeloid metaplasia. In multiple Phase 1 studies, GX15-070 was well-tolerated and resulted in clinical and biological activity.

The study, which is currently available in the online edition Blood, is titled, "Pre-clinical studies of the pan-Bcl inhibitor obatoclax (GX15-070) in multiple myeloma," was led by Dr. Suzanne Trudel, et al., of the Mayo Clinic of Medicine, Scottsdale, AZ, and Princess Margaret Hospital, Toronto, ON. The report will also appear in the print edition of Blood.

About Multiple Myeloma (MM)

Multiple myeloma is a type of cancer caused by malignant plasma cells that are spread throughout the bone marrow, resulting in bone erosion and interference with bone marrow and immune system function. MM is incurable and is characterized by frequent early responses to treatment followed by relapse. The American Cancer Society estimates that nearly 11,000 Americans will die of MM in 2007, and the 5-year survival rate for the disease is approximately 33 percent.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers. Gemin X is privately held and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
or
Gemin X Biotechnologies
Sherri Carenzo, 610-640-5735 Ext. 16
scarenzo@geminx.com


'"/>




Page: 1 2

Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces the reporting of data from ... Hydrochloride for Injection with the Delcath Hepatic Delivery ... presentation at the Society of Surgical Oncology (SSO) ...
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... focus on Omega-3 therapies for cardiovascular disease and overall ... 763,752 common shares of the Corporation (the "Common Shares"). ... period of December 5 th , 2014 to March ... that is due on or before April 1, 2015. ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... , MOUNTAIN VIEW, Calif., Dec. 14 Alexza Pharmaceuticals, ... submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... is an inhalation product candidate being developed for the rapid ... The IND for Staccato loxapine was filed ...
... , DENVER, Dec. 14 Corgenix Medical Corporation (OTC ... diagnostic test kits, and BG Medicine, Inc. (BGM), a ... agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products ... BG Medicine. BG Medicine is seeking regulatory clearance in ...
Cached Medicine Technology:Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2
(Date:3/27/2015)... March 27, 2015 Ticket Down is a ... CenturyLink Center in Omaha, Nebraska on Friday, May 8th ... more concert dates will be added in Omaha as Garth ... demand. , The Garth Brooks World Tour is continuing its ... announcement that Garth Brooks and Trisha Yearwood will bring their ...
(Date:3/27/2015)... March 27, 2015 DrugDev announced company ... Easy was named to the 2015 Philadelphia Business Journal ... list spotlights 40 dynamic, up-and-coming leaders less than 40 ... involvement. Winners are honored at an awards program in ... Philadelphia Business Journal. , Lyn Kremer, Publisher of the ...
(Date:3/27/2015)... Endure Yoga is launching WOD (Workout ... This new program matches yoga poses with functional fitness ... down. This program utilizes yoga to improve recovery, prevent ... , Karen Lefurgy, competitive athlete at CrossFit ... I started Crossfit® training, but quickly, due to time ...
(Date:3/27/2015)... According to Health Day , on March ... Syndrome (NAS) are causing alarm for Florida officials. Infants ... for a month of their lives- and can experience ... The condition is precipitated by drug use during pregnancy. ... employing medically assisted drug treatment) will also inflict NAS ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 SMI (Silicon ... announced it has launched the SM1120 MEMS based ultra-miniature ... The microsensor profile at only 220um x 75um ... to reach challenging locations. With industry leading in ... the SM1120 provides a broad operating pressure range from ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2
... on the Judiciary Committee staff of Senator Tom Coburn, Mary ... as Of Counsel to assist in spearheading America,s ... confirmation of U.S. Supreme Court nominee Judge Sotomayor. , ... am very pleased to have Mary join our team. ...
... with poor prognosis. This warrants the development of ... have demonstrated poor efficacy of adenoviral gene therapy ... on pancreatic cancer cells such as the coxsackie ... seems a promising option to improve adenoviral entry ...
... 2009 While Ontario women live longer than men, ... and chronic conditions, according to a new women,s health ... What,s more, low-income women have more chronic conditions, greater ... high-income groups. While inequities in health among men ...
... donations exceed expectations , , BIRMINGHAM, England, June ... world of a crippling and potentially fatal disease, Rotary ... toward its US$200 Million Challenge, a fundraising effort to ... Chair Jonathan Majiyagbe announced the new figure to an ...
... ... New Depreciation Wizard Feature for its Asset Tracking Application, Passport Assets, Enabling its Customers to ... , ... 23, 2009 -- ASAP Systems today announced the release of a depreciation wizard ...
... , Incentive Programs Driving Activities and Behavior Changes to Reduce ... ( http://www.incentone.com ), the leading provider ... health care industry, announced today that ... millionth health milestone. The 2 million milestones driven by IncentOne,s ...
Cached Medicine News:Health News:Mary Harned Joins Americans United for Life, Set to Oppose Sotomayor Confirmation 2Health News:Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells 2Health News:Ontario women live longer but don't prosper: Study 2Health News:Ontario women live longer but don't prosper: Study 3Health News:Ontario women live longer but don't prosper: Study 4Health News:Rotary Marks Progress in Drive to Eradicate Polio 2Health News:Rotary Marks Progress in Drive to Eradicate Polio 3Health News:ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inventory 2Health News:IncentOne Achieves 2 Millionth Health Milestone 2
This design features a solid red iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medicine Products: